Roche Holding AG will add manufacturing capacity in China to serve the country’s growing market, making it the latest ...

SALES FORECAST: The Swiss pharma giant's third-quarter sales are forecast at 14.89 billion Swiss francs ($17.22 billion), according to a consensus of 11 analysts' estimates compiled by Visible Alpha.

The company entered into an agreement with Roche Holdings AG (OTC:RHHBY ... cash position to support future growth. Scholar Rock Holding Corp (SRRK) showcases promising developments in its ...

Shares of Roche Holding AG (OTCQX:RHHBY) pulled back this month after the disappointing obesity pipeline updates where both the injectable and oral candidates showed poor tolerability. The company ...

Roche Holding AG has more than five medicines that it could combine with weight-loss drugs, Chief Executive Officer Thomas Schinecker said, as the Swiss drugmaker tries to crack the pharmaceutical ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

View Roche Holding AG (RHHBY) current and estimated P/E ratio data provided by Seeking Alpha.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...